



Poster presentation Code: G-84691



Studying of emerging immunotherapies in Acute Myeloblastic Leukemia with poor prognosis

Hanieh savari ¹, mohammad khani-Eshratabadi ^{1,2*}

1. Department of Medical Laboratory Sciences, Kashmar School of Nursing, Mashhad University of Medical sciences, Mashhad, Iran


2. Department of Hematology and Blood Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.



• Introduction :


Acute myeloblastic leukemia (AML) leads to the production and proliferation of abnormal blast cells from the bone marrow (BM) and is an aggressive and heterogene disease, poor prognosis due to various genetic alterations and abnormalities

advances in immunotherapy employ monoclonal and bispecific antibodies, chimeric antigen receptor (CAR) T cells, immune checkpoint inhibitors (ICIs) and vaccines provide an alternative pathway for AML treatment.






• Material & Method





• Results





• Conclusion:

There is no doubt that the landscape of treating AML is becoming more and more complex. However further advances and clinical applications of immunotherapy for AML are awaited

should be better investigated other emerging treatment methods besides immunotherapy

stem cell therapy

exosome

microvesicles derived from mesenchymal stem cells

gene therapy

